Results 131 to 140 of about 59,251 (307)
Sustainability in Analytical Chemistry Illustrated by Pharmaceutical Nitrosamine Testing
ELECTROPHORESIS, EarlyView.ABSTRACT Following the valsartan scandal in 2018, the testing of drug substances and drug products for N‐nitrosamines has become a critical and mandatory quality control measure. The European Pharmacopoeia chapter 2.5.42 currently describes three analytical methods for this purpose: HPLC–MS/MS, GC–MS, and GC–MS/MS.
Felix Bredendiek +2 more
wiley +1 more source
Synergistic effects of cardiac resynchronization therapy and drug up-titration in heart failure. is this enough? [PDF]
, 2015 This editorial refers to ‘Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival’, by C.T.
FRANCIA, Pietro, VOLPE, Massimo
core +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism.
Yan‐Jun Yang, Jiu‐Sheng Li
wiley +1 more source
From ARB to ARNI in Cardiovascular Control [PDF]
, 2016 Coexistence of hypertension, diabetes mellitus and chronic kidney disease synergistically aggravates the risk of cardiovascular and renal morbidity and mortality.
Danser, A.H.J. (Jan) +3 more
core +1 more source
Med Research, EarlyView.ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang +22 more
wiley +1 more source
Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. [PDF]
, 2017 Importance: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ( guided therapy ) with inconsistent ...
Adams, Kirkwood F. +15 more
core +3 more sources
British Journal of Pharmacology, EarlyView.Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy +10 more
wiley +1 more source
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension [PDF]
, 2017 The efficacy and safety of azilsartan medoxomil (AZL-M) were evaluated in African-American patients with hypertension in a 6-week, double-blind, randomized, placebo-controlled trial, for which the primary end point was change from baseline in 24-hour ...
Bakris, George L. +9 more
core +2 more sources
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen +7 more
wiley +1 more source